Figure 6. Suppression of DNA damage response signal attenuated the protection of SeMet against CoNPs. An inhibitor of ATM/ATR (CGK733) was added to CD34+ HSC/HPCs treated with SeMet and CoNPs. Afterwards, cells underwent cell viability (A) and apoptosis (B) assays. BRCA1 and UBE2K were silenced in CD34+ HSC/HPCs, followed by cell viability (C), apoptosis (D), cell cycle (E) and western blot assays (F). ***p < 0.001 vs. control cells that did no subjected to any treatments. ##p < 0.01 and ###p < 0.001 vs. cells treated with CoNPs alone. &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. cells treated with SeMet and CoNPs in combination.